The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, June 26, 2025 /PRNewswire/ — USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns around drug affordability and access. These headwinds are forcing a shift in expectations — placing the burden of innovation on the private sector, where companies like Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Citius Oncology, Inc. (NASDAQ: CTOR), ADC Therapeutics SA (NYSE: ADCT), and OS Therapies Incorporated (NYSE-American: OSTX).
The shift reflects more than a funding gap — it signals a structural realignment in how cancer breakthroughs may be brought to market. As public systems face pressure and timelines extend, nimble biotech firms are advancing targeted treatments, combination trials, and regulatory conversations once dominated by legacy institutions. Against this backdrop, market watchers see a pivotal window opening for investors willing to back the next wave of oncology innovation.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new chapter with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. With a background in high-value biotech transactions and late-stage development strategy, Kelly brings experience that may help position the company for its next phase of clinical and corporate progress.
Prior to joining Oncolytics, Kelly was General Counsel at Ambrx Biopharma, where he played a key role in the company's $2 billion acquisition by Johnson & Johnson. He also advised a range of life sciences firms on partnerships, licensing, and M&A during his tenure at Kirkland & Ellis LLP and Lowenstein Sandler LLP. His arrival comes as Oncolytics continues advancing pelareorep, a viral-based immunotherapy being evaluated in combination with checkpoint inhibitors and other agents across multiple cancer indications.
'Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients,' said Jared Kelly, CEO of Oncolytics Biotech. 'With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders.'
Kelly's appointment appears aligned with a focused strategy: advancing pelareorep through late-stage development while maintaining capital efficiency and openness to potential partnerships. The company's lead program continues to generate data that support further investigation across several difficult-to-treat cancers.
Pelareorep already holds FDA Fast Track designation in two separate indications — metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) — a distinction that highlights regulatory interest in its potential.
Across clinical studies, the viral-based immunotherapy has consistently shown signs of immune activation, combinability with checkpoint inhibitors and chemotherapy, and efficacy in heavily pretreated populations.
In mPDAC, a Phase 2 cohort from the trial has reported objective response rates (ORR) above 60% in tumor-evaluable patients, exceeding historical benchmarks for this indication. Additional analyses have noted extended two-year survival rates compared to previous benchmarks. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) observed overall survival trends that support continued clinical evaluation.
Elsewhere, a Phase 2 anal cancer cohort combining pelareorep with a checkpoint inhibitor demonstrated partial or complete response rates that exceeded historical control trials for checkpoint inhibitor monotherapy, suggesting potential utility beyond the company's lead programs.
'Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date,' said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. 'We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors.'
Kelly's compensation framework includes equity-based awards and performance-linked incentives tied to future financings and strategic outcomes. The structure is designed to align leadership priorities with long-term shareholder value while reinforcing a disciplined approach to capital and partnership development.
As multiple cohorts advance within the GOBLET study — including those in pancreatic and anal cancers backed by external funding and regulatory support — Oncolytics appears positioned to continue its progress with a blend of clinical momentum, financial flexibility, and sharpened strategic direction.
Prior to Kelly's appointment, Oncolytics presented new data from its GOBLET trial at the 2025 ASCO Annual Meeting, highlighting pelareorep's ability to stimulate both innate and adaptive immune responses in metastatic pancreatic cancer. With fresh clinical insights and new leadership in place, the company appears positioned to advance both its scientific and strategic priorities in tandem.
CONTINUED… Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/
In other recent industry developments and happenings in the market include:
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has entered into a strategic partnership with Fosun Pharma to accelerate development of TEV-56278, a novel anti-PD1-IL2 immunotherapy designed using its proprietary ATTENUKINE™ technology.
'This partnership with Fosun Pharma in the development of our internally developed TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy with the potential to treat devastating cancers, is the latest advance to ensuring acceleration of our pipeline,' said Eric Hughes, MD, PhD, Executive Vice President, Teva Global R&D and Chief Medical Officer. 'TEV-56278 demonstrates the strength of Teva's innovative drug development capabilities and how strategic partnerships with companies such as Fosun Pharma play a pivotal role in advancing therapies on behalf of patients.'
This investigational fusion protein is aimed at selectively delivering IL-2 to PD-1+ T cells, potentially enhancing anti-tumor response while limiting toxic side effects. Under the agreement, Fosun will lead clinical, manufacturing, and commercial activity in China and parts of Southeast Asia, while Teva retains global rights elsewhere.
Citius Oncology, Inc. (NASDAQ: CTOR) recently announced that it expects to commercially launch LYMPHIR™ in 2025 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), pending FDA approval.
'We've made steady and meaningful progress toward commercialization over the past several months,' said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma. 'With our supply chain secured, market access supported, and no anticipated impediments to reimbursement, we are encouraged by the momentum we've built. These efforts are pivotal as we transition into a commercial-stage company and believe the planned 2025 launch of LYMPHIR has the potential to be an important inflection point for both the company and the CTCL community.'
ADC Therapeutics SA (NYSE: ADCT) recently reported updated Phase 2 data from an investigator-initiated trial of ZYNLONTA® in relapsed/refractory marginal zone lymphoma (r/r MZL), showing an 84.6% overall response rate and a 69.2% complete response rate.
'Based on the updated Phase 2 IIT data to be shared at ICML, we are encouraged by the potential opportunity in r/r MZL and look forward to seeing additional data, as the trial expands to other sites.' said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. 'As this trial progresses, assuming the results continue to be positive, we plan to potentially pursue a regulatory pathway and compendia in parallel as soon as sufficient data are available.'
The trial also showed encouraging durability, with complete responses maintained in 17 of the 18 patients who achieved a complete response and progression-free survival of 92.9% at 12 months. ZYNLONTA was generally well tolerated, with safety findings consistent with its existing clinical profile.
OS Therapies Incorporated (NYSE-American: OSTX) received positive written feedback from the FDA following a Type D meeting regarding its lead candidate, OST-HER2, for pediatric lung metastatic osteosarcoma.
'We are pleased with the feedback we received from the FDA regarding the use of external control comparators in settings where placebo-controlled randomization trials are not feasible – particularly in rare pediatric diseases such as the indication treated by OST-HER2 ,' said Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies. 'Moreover, we received additional collaborative input regarding suggested statistical methods as we seek to compare OST-HER2 active treatment with external control arm(s) to support a Biologics Licensing Application (BLA) via the Accelerated Approval Program. Taken together, the feedback gives us insight on the FDA's current position and allows us to be fully prepared for the End of Phase 2 Meeting.'
The agency supported the company's proposed use of external comparators in its Phase 2b trial, potentially laying groundwork for accelerated approval. OS Therapies has submitted requests for an End of Phase 2 Meeting and Breakthrough Therapy Designation, with regulatory filings expected to advance in late 2025.
Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/
CONTACT:USA NEWS GROUPinfo@usanewsgroup.com(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Video – https://www.youtube.com/watch?v=kawrtZfPysQLogo – https://mma.prnewswire.com/media/2603685/5390335/USA_News_Group_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/the-900-billion-question-who-will-deliver-the-next-cancer-breakthrough-302492487.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
an hour ago
- The Star
Hong Kong has potential to become green marine fuel hub with Beijing's backing
Hong Kong can become a regional trading hub for green marine fuel and help augment China's influence on supply and pricing, according to an industry player. 'Hong Kong's advantages lie in its roles as an international free port, shipping and financial hub, and the government's willingness to support energy transition and green finance,' said Leo Yang Xiaohu, president of CIMC Enric Holdings, which built the city's first hydrogen refuelling station and related infrastructure in 2023. By boosting domestic green fuel demand, Hong Kong can help Beijing fend off trade barriers overseas and enhance the nation's influence on its pricing, Yang said in an interview on Wednesday. 'If Hong Kong can develop a trading hub, we can have a bigger say in green fuel trading and pricing,' Yang said. The European Union, the world's largest biodiesel market, last August imposed anti-dumping duties on Chinese biodiesel, prompting producers to seek alternative markets. Last year, the government published an action plan to develop Hong Kong into a green fuel bunkering or shipping-fuel supply centre. In February, Financial Secretary Paul Chan Mo-po pledged to provide tax exemptions for importing and consuming green methanol. Secretary for Transport and Logistics Mable Chan Mei-po said in a statement on Wednesday that the Marine Department would gazette the code of practice for methanol bunkering this month. The Marine Department will also launch a scheme this year offering incentives of up to HK$1 million (US$127,400) for companies that provide green fuel bunkering. The city could also offer vessel operators financial and customs clearance advantages for buying green marine fuel, Yang said. He added that banks could provide green financing and help shippers trade carbon emission permits to incentivise the use of green fuel and the construction of supporting infrastructure. CIMC Enric, a liquefied natural gas storage and logistics equipment maker, is a subsidiary of state-backed container maker China International Marine Containers (Group). The company is constructing a plant in Zhanjiang, western Guangdong Province, with an annual production capacity of 50,000 tonnes of green methanol converted from agricultural and forestry waste. Yang said the plant would be ready in August, and pilot production was expected to start in October. The plant's capacity could be raised to 200,000 tonnes by next year, he added. Compared with conventional fuel, renewable methanol could slash carbon dioxide emissions by up to 95 per cent, according to the Methanol Institute, a global trade association representing the world's leading methanol producers, distributors and technology companies. The demand for green fuel will surge as shipping firms align their fleets to meet the International Maritime Organisation's targets to cut greenhouse gas emissions by at least 20 per cent by 2030 from 2008 levels, and by at least 70 per cent by 2040. A few bunkering firms had expressed an interest in green methanol from CIMC Enric, and some shipping firms were also interested, Yang said. The company's equipment was capable of processing five types of biomass waste, and it had secured enough waste supply to produce up to 250,000 tonnes of the fuel, he added. CIMC Enric signed an agreement on Wednesday with the Transport and Logistics Bureau to supply green methanol for bunkering. Hong Kong and China Gas (Towngas), the piped-gas supplier, also signed an agreement with the bureau to supply green methanol that complies with international standards and to use the city as a trading and settlement hub for green maritime fuel. Towngas also said the annual capacity of its waste-to-green methanol plant in Inner Mongolia would rise to 150,000 tonnes by the end of the year from 100,000 tonnes currently. The company said it planned to build multiple plants with Foshan-based natural gas distributor Foran Energy, with an overall annual capacity of one million tonnes. The first facility, with a capacity of 200,000 tonnes, would be commissioned in 2028, it said. -- SOUTH CHINA MORNING POST
The Sun
an hour ago
- The Sun
Balancing innovation and responsibility
MALAYSIA is racing toward a digital future – one powered by a booming data centre industry projected to consume over 20 GW of electricity by 2040, as forecast by the Ministry of Energy Transition and Water Transformation (Petra). This explosive growth is unlocking vast economic potential but also highlighting the way that Malaysia must balance the demands of a thriving digital economy with the environmental challenges it brings. According to Deputy Investment, Trade and Industry Minister Liew Chin Tong, Malaysia's data centre industry has witnessed substantial growth, with investments totalling RM184.7 billion from 2021 to December 2024 thanks to the increasing demand for cloud computing, artificial intelligence (AI), and digital services. Our proximity to Singapore, which imposed a moratorium on new data centres due to resource constraints, has further enhanced Malaysia's appeal. Local communities, particularly in Johor and Selangor, are seeing new employment opportunities and infrastructure development as global players establish operations in these regions. Reuters reported that the investment made by one of the world's largest technology companies in Malaysia is expected to generate approximately US$10.9 billion in new revenues over the next four years and create more than 37,000 jobs, demonstrating the sector's potential to drive national growth. The economic benefits are clear. Faced with significant opportunities for growth, it's all the more important that we carefully consider our responsibilities to the wider community, and the impacts on the places we live and work. The impact that data centres pose to the environment needs to be carefully managed. Malaysia's Ministry of Energy Transition and Water Transformation has projected that electricity demand from data centres, which require continuous power and extensive cooling systems, will reach 7.7 GW by 2030 and could surge to 20.9 GW by 2040. To mitigate these issues, the government has implemented several forward-looking initiatives. The National Energy Transition Roadmap (NETR), introduced by the Ministry of Economy, aims to achieve 70% renewable energy capacity by 2050, an ambitious leap from the current 25%. Additionally, the Corporate Renewable Energy Supply Scheme (CRESS) allows data centre operators to source energy directly from green power producers, bypassing the national grid. The significant amount of water required to cool data centres have also raised alarms. The National Water Services Commission (Suruhanjaya Perkhidmatan Air Negara/SPAN) warns that unchecked water usage by data centres could contribute to a water crisis. In response, several strategies have been adopted to manage water consumption. Water Usage Effectiveness metrics help track and promote efficient water management practices within data centres while companies have collaborated with state-owned entities to develop recycled water supply schemes, reducing reliance on potable water. There is also growing interest in alternative cooling technologies, including immersion cooling, which can significantly lower both water and energy consumption. These are important strategies, and it is critical that we continue to build on this work to ensure that we are balancing our economic growth with the urgent need for environmental stewardship. We know that collaboration between public and private sectors is an essential part of ensuring responsible growth of any sector, so it's great to see that the government has taken a proactive stance in regulating and guiding the development of data centres. The Ministry of Investment, Trade, and Industry's guidelines outline best practices for energy and water efficiency, safety, scalability, and the adoption of smart technologies. Environmental Impact Assessments are mandatory for projects with significant ecological implications to ensure new data centres consider and mitigate environmental impacts. Government incentives, including potential tax breaks, also encourage green practices such as renewable energy integration, advanced cooling systems, and efficient water usage. Beyond government action, industry stakeholders are actively contributing to responsible practices within the data centre ecosystem. The YTL Group 2024 Sustainability Report highlighted that YTL Green Data Centre Park in Johor integrates advanced technologies and energy-efficient designs including solar-powered infrastructure, advanced cooling systems, and rainwater harvesting systems to minimise environmental impact while ensuring high performance. With an expected capacity of 500MW, the park stands as a regional benchmark for balancing technological advancement with environmental responsibility. We have also seen leading global data centre providers focusing on energy efficiency to meet their carbon neutrality goals and investing in rooftop solar panels and virtual power purchase agreements for solar farms. Addressing the dual priorities of economic development and environmental sustainability requires a multi-pronged approach. One potential solution is the development of responsible data centre certification programmes. By creating a national certification that evaluates facilities on their energy efficiency, water usage, and carbon emissions, the government can incentivise more sustainable choices. Another opportunity lies in regional collaboration, where Southeast Asian nations work together to share technologies, regulatory best practices, and renewable energy resources. Investment in research and development is also crucial. Government grants and private sector initiatives can support the creation of advanced cooling systems, AI-driven energy management, and water recycling innovations tailored to Malaysia's tropical climate. Lastly, transparent reporting and environmental accountability must be prioritised to ensure measurable progress and public trust. Malaysia stands at a pivotal crossroads: the path forward must blend innovation with responsibility. By fostering collaboration across government, industry, and academia, Malaysia can lead Southeast Asia not just in digital capability, but in responsible digital leadership. Achieving this vision will require actionable policies, measurable standards, transparent reporting, and shared accountability.
The Sun
an hour ago
- The Sun
GCC free trade talks signal strategic economic realignment
MALAYSIA'S move to sign the Free Trade Agreement (MGFTA) negotiations with the Gulf Cooperation Council (GCC) marks a pivotal step in expanding its economic reach beyond traditional partners. With GCC members – including Saudi Arabia, the UAE, Qatar, and others representing a collective GDP of over US$2 trillion (RM8.5 trillion), this agreement lays the groundwork for deeper trade and investment linkages with one of the world's most capital-rich regions. At its core, the MGFTA aims to reduce tariff and non-tariff barriers, boosting trade in high-impact sectors like palm oil, electrical and electronics, petrochemicals, halal products, and even digital services. It follows the Comprehensive Economic Partnership Agreement (CEPA) between Malaysia and the UAE signed earlier this year, indicating a broader policy shift to strengthen ties with the Middle East. This agreement comes at a time when global trade is increasingly fragmented by geopolitical tensions and protectionist policies. For Malaysia, forging new trade corridors is more than just an economic opportunity – it is a hedge against over-reliance on major power blocs and a chance to position itself as a key node in South-South economic cooperation. In addition to trade flows, the MGFTA is expected to encourage greater foreign direct investment from GCC members into Malaysia. Sovereign wealth funds like Saudi Arabia's PIF and the UAE's Mubadala are actively seeking investment diversification, and Malaysia's robust manufacturing base, green energy ambitions, and Islamic finance expertise make it a compelling destination. This is especially promising for sectors such as logistics, infrastructure, and renewable energy – all areas that align with both GCC diversification strategies and Malaysia's own Madani economic agenda. The formal launch of FTA negotiations between Malaysia and the Gulf Cooperation Council (GCC) signals deeper structural shifts that Malaysian investors should take seriously – not just as a policy headline, but as a potential reorientation of capital, demand, and strategic partnerships across multiple sectors. Malaysia's stronghold in halal certification and production could see renewed momentum. As trade barriers fall, local companies in halal food, personal care, pharmaceuticals, and logistics may benefit from easier access to GCC markets where demand is both high and culturally aligned. Public-listed firms involved in food processing, logistics, or halal certification services stand to gain from both volume expansion and brand credibility in a growing export market. Increased interest from GCC sovereign wealth funds in Southeast Asia could drive participation in Malaysian infrastructure, property, and industrial projects. Investors should pay attention to companies involved in industrial park development, ports, and integrated logistics – particularly those already involved in government-linked or cross-border projects. Construction-related counters, especially those tied to public-private partnerships or industrial infrastructure, may also receive a boost in sentiment. As both Malaysia and the Gulf pursue energy transition agendas, the MGFTA may pave the way for bilateral collaboration in clean tech, solar, hydrogen, and sustainable infrastructure. This aligns with Malaysia's National Energy Transition Roadmap (NETR). Investors should look at firms engaged in solar EPC (Engineering, Procurement and Construction), grid technologies and project financing for renewable energy assets. In parallel, energy service providers operating in oilfield maintenance and engineering – especially those with GCC exposure – may also benefit if demand for technical partnerships grows. Malaysia's global leadership in Islamic finance could translate into new co-developed Shariah-compliant instruments, investment funds, and green sukuk frameworks. This opens opportunities for growth in both the finance sector and capital markets more broadly. Malaysian financial institutions that operate Islamic banking or takaful arms may find more collaborative opportunities with GCC counterparts, and investors should monitor any regulatory developments or joint announcements in this space. In short, the MGFTA has the potential to do more than lower trade barriers – it could reshape the flow of capital, the structure of incentives, and the future growth story for key Malaysian industries. For long-term investors, tracking these sectoral shifts early may offer a strategic edge as Malaysia deepens economic ties with one of the most liquid and investment-ready regions in the world. This article is contributed by Moomoo Malaysia dealing head Ken Low (pic). This commentary has not been reviewed by the SC.
